news
Preventative approach could reduce immunotherapy side effects
Research suggests that giving prophylactic treatment prior to immunotherapy could eliminate the need for the latter to be administered in hospitals.
List view / Grid view
Cytokine release syndrome (CRS)
article
Developing point-of-care CAR T manufacturing
Driven by technological advances there is now increased scope for point-of-care manufacturing of CAR T-cell therapy. Arnon Nagler, Professor of Medicine at Tel Aviv University, discusses key benefits, challenges and lessons learned from developing an in-house programme.
news
CAR-T therapy safe for relapsed or refractory T-cell malignancies, finds study
A Phase I trial revealed that Bioheng Biotech’s chimeric antigen receptor (CAR) T-cell therapy drug RD13-01 was safe for use and that it could reduce malignant tumours.
news
IL-6 signalling blockade alleviates severe COVID-19 symptoms
Scientists have shown that treating COVID-19 patients with severe respiratory complications with an IL-6 signalling inhibitor improved their symptoms.
